Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Saved in:
Bibliographic Details
Title: Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.
Authors: Haggenburg S; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands., Pothast CR; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Hofsink Q; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands., Haverkate NJE; Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Bhoekhan MS; Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Claireaux M; Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., van Binnendijk RS; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Hartog GD; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.; Department of medical immunology, Laboratory of Medical Immunology, Radboud University Medical Center, Nijmegen, The Netherlands., Lissenberg-Witte BI; Department of Epidemiology and Data Science, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, The Netherlands., de Vries RD; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands., van Tuijn C; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Biemond BJ; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Nur E; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Geurts van Kessel CH; Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands., Mutsaers PGNJ; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands., Broers AEC; Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands., Goorhuis A; Department of Infectious Diseases, Centre of Tropical Medicine and Travel Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Nijhof IS; Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.; Department of Internal Medicine-Hematology, St. Antonius Hospital, Nieuwegein, The Netherlands., van Gils MJ; Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Heemskerk MHM; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Hazenberg MD; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Haematopoiesis, Sanquin Research, Amsterdam, The Netherlands., Rutten CE; Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands., van Meerloo JJH, Smit GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra N, Kant IMJ, Graas T, Toussaint B, de Jong S, Darwesh S, Mahes SS, Kamminga D, Koelewijn M, Faber G, Beaumont G, Engel MD, Pierie RCN, Janssen SR, Faber G, Groen K, Burger JA, Bouhuijs JH, Baars PA, van Dijkman E, Heijmans J, Witte YY, Nahui Palomino RA, Omar SZ, Zweegman S, Kater AP, van den Vegt C, Arends-Halbesma I, de Pater E, Dijkstra MJ, van Beek J, Rots NY, Rijnstra ES, de Rooij DM, Sanders RW, Poniman M, Olijhoek W, van Rijswijk J, Beaumont T, Çetinel L, Schellekens L, den Hartogh YM, Cloos J, Weijers SS, Tonouh-Aajoud S, Avci S, Roelandse-Koop E, Dik WA, Vogels-Nooijen S
Source: Blood advances [Blood Adv] 2026 Feb 24; Vol. 10 (4), pp. 1068-1081.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025017239